The coronavirus disease 2019 (COVID-19) has been linked to many systemic inflammatory reactions and high morbidity and mortality rates. Patients with gastrointestinal symptoms progress more rapidly than others. COVID-19 induced acute pancreatitis is not common and can occur in cases of mild infection or even after resolution of the viral infection. We report a case of a 71-years-old male with multiple comorbidities that was admitted as a case of COVID-19 pneumonia for 10 days. Afterwards, the patient was discharged with resolution of the infection and presented two days later with signs of acute pancreatitis. On further investigation, it was confirmed that his acute pancreatitis was due to his previous COVID-19 infection. In conclusion, COVID-19 induced acute pancreatitis is serious and can develop rapidly. Close monitoring and admission are necessary to keep proper hydration.

Amiodarone is a class 3 antiarrhythmic drug which may be associated with thyroid dysfunction. Amiodarone-induced thyrotoxicosis (AIT) is classified as type 1 (AIT 1; which may develop in the presence of latent autoimmune hyperthyroid condition) or type 2 (AIT 2; which develops in an apparently normal thyroid resulting from destructive thyroiditis). AIT 1 routinely requires treatment with thionamides, whereas AIT 2 is treated with steroids. Resistance to the conventional treatment of hyperthyroidism is not commonly found in clinical practice. This report discusses a case of AIT 2 resistant to conventional treatment. Despite being on high doses of carbimazole and steroids (prednisolone), the patient remained thyrotoxic. Cholestyramine, a bile salt sequestrant, was used as an adjunctive therapy resulting in significant clinical and biochemical improvement. The patient subsequently became euthyroid and is being followed up in endocrine clinic.